Flamel Technologies' NDA for Bloxiverz gets FDA nod

06/4/2013 | RTT News

The FDA has granted Flamel Technologies approval for its new drug application for Bloxiverz. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents following surgery.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN